Humacyte (HUMA): CFO sold ~$41K

~$41K

Approx. value · 46K sh @ $0.8967

267K

Holds after · shares reported

Traded

May 18, 2026

Filed

May 20, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 19, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
2. Mar 19, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
3. Apr 21, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
4. May 4, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global…”
5. May 18, 2026 · this disclosureInsiderCFO sold ~$41K of HUMA shares in the open market

What came next

1. May 18, 2026Insider · 2 peopleInsiders: 1 purchase (~$10K), 1 sale (~$41K)
2. May 19, 2026Insider · Bought outside the usual windowDirector purchased ~$50K of HUMA shares in the open market
3. Jun 9, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
4. Jun 10, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
5. Jul 31, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq…”
6. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results
7. Aug 17, 2026Insider · Their first buy on recordDirector purchased ~$18K of HUMA shares in the open market
8. Aug 20, 2026InsiderDirector purchased ~$6.9K of HUMA shares in the open market
9. Sep 14, 2026Insider · 8 days before an 8-KDirector purchased ~$5.6K of HUMA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Humacyte

For Humacyte, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HUMA page.

Other recent filings by Dale A. Sander, CFO and Chief Corp. Dev. Off

• SEC Form 4 at Humacyte (HUMA)Apr 14, 2025

The full history of Dale A. Sander, CFO and Chief Corp. Dev. Off is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Humacyte

• SEC Form 4Sep 15, 2026
• SEC Form 4Aug 21, 2026
• SEC Form 4Aug 19, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026

Everything OQRO holds on this company is on its HUMA page.